PreludeDx Appoints Chris Emery, VP of Strategic Marketing and Business Development

LAGUNA HILLS, Calif., Feb. 8, 2024 /PRNewswire/ — Prelude Corporation (PreludeDx^™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, now declared the appointment of Chris Emery to the freshly produced posture of VP of Strategic Promoting and Small business Enhancement. This position is a strategic addition to the leadership team as PreludeDx expands market adoption of its ductal carcinoma in situ (DCIS) risk evaluation check and proceeds enhancement of its molecular screening portfolio into early-stage invasive breast cancer.

“We go on to increase our products portfolio of early-phase breast cancer molecular diagnostics and accelerate adoption of our DCISionRT test among the clinicians and people for shared client choice building and enhanced outcomes,” said Dan Forche, President and CEO of PreludeDx. “With his intensive knowledge in healthcare and particularly molecular diagnostics, I am happy to welcome Chris to PreludeDx’s management crew. In this freshly designed position, Chris will concentrate on bringing our future precision drugs checks for early-stage breast most cancers to current market and discover business growth possibilities which will aid to extend the Prelude business and solution portfolio.”

Chris delivers much more than 25 years of practical experience in healthcare throughout laboratory expert services, medical machine and biopharmaceutical companies, with senior leadership roles in marketing and advertising, income and small business growth in the cancer diagnostics market. He joins PreludeDx from HALO Precision Diagnostics exactly where he served as the Main Organization Officer – Molecular Diagnostics. He was responsible for encouraging HALO create out its scientific laboratory in get to integrate breast cancer-targeted precision diagnostic tests with radiology products and services to much better serve doctors and patients in the local community health care environment. Earlier, Chris served in several leadership roles with Menarini, Abbott, Novartis and LabCorp, in which he launched impressive tests for personalized cure selections for cancer clients. He acquired his Government MBA from Pepperdine University and his BA in communications experiments from College of California – San Diego.

“I am excited to be part of the workforce at PreludeDx at such a transformative level in time,” said Emery. “I glance forward to performing carefully with our crew to accelerate adoption and grow scientific utility of our novel precision diagnostics portfolio.”

About DCISionRT for Breast DCIS

DCISionRT is the only possibility evaluation take a look at for patients with ductal carcinoma in situ (DCIS) that predicts radiation remedy reward. Individuals with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into bordering breast tissue. In the US, over 60,000 ladies are freshly diagnosed with DCIS each individual 12 months. DCISionRT, produced by PreludeDx on technology licensed from the College of California San Francisco, and created on research that began with funding from the Nationwide Most cancers Institute, enables physicians to far better recognize the biology of DCIS. DCISionRT combines the newest improvements in molecular biology with possibility-dependent assessment scores to assess a woman’s individual tumor biology alongside with other pathologic danger aspects and supply a customized recurrence danger. The exam offers a Decision Rating^™ that identifies a woman’s risk as reduced or elevated. In contrast to other chance evaluation tools, the DCISionRT examination combines protein expression from seven biomarkers and four clinicopathologic aspects, utilizing a non-linear algorithm to account for many interactions between individual components in purchase to better interpret complicated organic information and facts. DCISionRT’s intelligent reporting delivers a woman’s recurrence possibility immediately after breast conserving operation alone and with the addition of radiation remedy. In change, this new information may perhaps support clients and their medical professionals to make much more informed therapy conclusions.

About PreludeDx

PreludeDx is a leading individualized breast cancer diagnostics enterprise devoted to serving breast most cancers sufferers and doctors around the globe. Founded in 2009 with technologies accredited from College of California San Francisco, PreludeDx has focused on acquiring precision breast most cancers applications that will influence a patient’s remedy decision. Our mission is to present clients and doctors with impressive technologies that increase affected individual outcomes and lower the in general price tag load to the healthcare procedure. Prior to producing a treatment determination, Know Your Danger^™. PreludeDx is a Fjord Ventures portfolio corporation.

For a lot more info on how PreludeDx is building a distinction for sufferers, remember to pay a visit to the Company’s web-site: https://preludedx.com and adhere to us on Twitter @PreludeDx, Fb, Instagram and LinkedIn.

PreludeDx, the PreludeDx emblem, DCISionRT, the DCISionRT brand, DecisionTree, Selection Rating, The DCIS Examination, Know Your Chance and Your Biology, Your Choice are logos of Prelude Company or its wholly owned subsidiaries in the United States and international countries.

Resource PreludeDx